{"id":"NCT01509547","sponsor":"Medical University of South Carolina","briefTitle":"Varenicline for Adolescent Smoking Cessation","officialTitle":"A Randomized Controlled Trial of Varenicline for Adolescent Smoking Cessation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-08","primaryCompletion":"2018-01-26","completion":"2018-01-26","firstPosted":"2012-01-13","resultsPosted":"2019-03-11","lastUpdate":"2020-07-01"},"enrollment":157,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Nicotine Dependence"],"interventions":[{"type":"DRUG","name":"Varenicline","otherNames":["Chantix"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"varenicline","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a placebo-controlled smoking cessation treatment study for adolescents ages 14-21. After assessment and inclusion into the study, participants will be randomized to receive a 12-week double blind course of varenicline or placebo.","primaryOutcome":{"measure":"Number of Participants With Cotinine-confirmed 7-day Point Prevalence Abstinence at the End of Treatment","timeFrame":"7 days at end of treatment","effectByArm":[{"arm":"Varenicline","deltaMin":4,"sd":null},{"arm":"Placebo","deltaMin":4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"14 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["34611902","31609433"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":77},"commonTop":["nausea","viral upper respiratory tract infection","vomiting","headache","vivid dreams"]}}